ReviewCurrent opinion in hematology2014
Graft-versus-host disease: why have we not made more progress?
Review in Current opinion in hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03689894 (Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Medication nonadherence to immunosuppressants after adult allogeneic haematopoietic stem cell transplantation: a multicentre cross-sectional study.Bone marrow transplantation · 2017Trial
- Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD.Bone marrow transplantation · 2015Trial
- Trial
- Ruxolitinib Plus Extracorporeal Photopheresis for Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease.Journal of clinical medicine research · 2025Article
- Temporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement.International journal of hematology · 2025Article
- Panel of three cytokines predicts occurrence of aGVHD after allo-HSCT: a retrospective study.Frontiers in immunology · 2025Article
- Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program.Bone marrow transplantation · 2024Article
- A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore.Cost effectiveness and resource allocation : C/E · 2023Article
- Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Gamma delta T-cell reconstitution after allogeneic HCT: A platform for cell therapy.Frontiers in immunology · 2022Review
- Post Transplantation Bilirubin Nanoparticles Ameliorate Murine Graft Versus Host DiseaseFrontiers in immunology · 2022Article
- CD69+ resident memory T cells are associated with graft-versus-host disease in intestinal transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
- Comparison of the Efficacy of Topical Triamcinolone in Orabase and Curcumin in Orabase in Oral Graft-Versus-Host Disease.Journal of dentistry (Tehran, Iran) · 2017Article
- Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.Nature communications · 2017Article
- Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease.Bone marrow transplantation · 2017Article
- Hsp90 inhibition ameliorates CD4Immunity, inflammation and disease · 2016Article
- Biomaterials and host versus graft response: a short review.Bosnian journal of basic medical sciences · 2016Review
- Graft-versus-host disease affecting oral cavity. A review.Journal of clinical and experimental dentistry · 2015Review
- Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease.JAMA dermatology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewAlthough allogeneic hematopoietic stem cell transplantation (allo-SCT) is potentially curative for a number of hematologic malignancies, its use is limited by the development of acute and chronic graft-versus-host disease (GVHD). This potentially fatal complication occurs in approximately 50% of allo-SCT recipients. RECENT
findingsThe pathogenesis of acute and chronic GVHD remains poorly understood, methods to prevent it are largely unchanged over the last two decades, and response to front-line treatment with corticosteroids is suboptimal. For patients with steroid-refractory disease, response to second-line treatment is dismal. The prospective clinical studies evaluating new agents for GVHD have been hampered by the inconsistencies in design, making generalization difficult, and few multicenter studies have been conducted. SUMMARY: Advances have been made over the last decade in grading both acute and chronic GVHD, with the development of biomarkers that provide improved prognostic information in acute GVHD and National Institutes of Health Consensus Criteria for improved grading of chronic GVHD. This, along with the broad understanding of the need to conduct prospective studies with uniform inclusion criteria and endpoints leading to multicenter studies, will hopefully lead to advancements in the prevention of GVHD in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.